Clinical trial of lifestyle interventions for weight management in adults living with MS
Obesity can increase the risk of developing MS and may increase levels of disability in those with established MS. Losing weight can help improve more than just body size, but it can be difficult to do and needs the support of a healthcare team to aid behaviour change. This study will use a tested method […]
STRONG-MS: Bone health and muscle health in MS
This study is a randomised controlled trial evaluating ONERO™. This is a High-intensity Resistance and Impact Training (HiRIT) exercise intervention that has potential benefits for bone health and muscle strength in people with (MS). Qualified physiotherapists will supervise balance exercises, impact movements and weightlifting in twice-weekly, 30-minute sessions. Participation involves a total of 24 months. […]
PLATYPUS – the Australian extension of the OCTOPUS trial
PLATYPUS is the Australian extension of a revolutionary trial based in the United Kingdom (UK) called OCTOPUS, which aims to enroll participants in the UK and Australia over the next few years. OCTOPUS (including PLATYPUS) is a trial which will test multiple treatments with the aim to find one that can slow down, and ultimately […]
Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STOP-MS)
Multiple sclerosis (MS) is a potentially devastating disease of the central nervous system and progressive MS, which occurs in up to two-thirds is the most severe form. Current therapies for MS have limited effect in the progressive stage. Recent studies have confirmed that the primary cause of MS is latent infection with Epstein-Barr virus (EBV). […]
The MS Family Study
Researchers from the Menzies Institute for Medical Research are seeking participants who come from families with multiple relatives affected by multiple sclerosis (MS). By analysing the genetic code of such families, the researchers want to better understand the inherited risk of MS.
ACT-Sydney Multiple Sclerosis (MS) cohort study
As part of the Our Health in Our Hands (OHIOH) project, researchers at the Australian National University and Sydney Adventist Hospital are working together to improve the clinical management and overall health and wellbeing of people living with multiple sclerosis (MS). In this study we are recruiting people with MS as well as people who […]
A clinical trial for patients with Myelin oligodendrocyte glycoprotein antibody disorder (MogAD)
This is a Global, Multicentre Phase III, Randomised, Double-Blind Clinical Trial. The study currently includes over 120 adults and is actively recruiting adolescents (12-18 years of age) with MOGAD from around the world. In Australia 3 sites are participating in the study, located in NSW.
MS Genetics Project (GEMS Study)
We need your help to investigate the Epstein-Barr Virus (EBV) strain that may play a crucial role in developing multiple sclerosis (MS). This study also aims to identify specific markers in the blood associated with onset and progression of MS. The knowledge gained will be used to greatly improve MS diagnosis, treatment and prevention.
Assisted Reproductive Technology in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders (ARTiMS)
The purpose of this study is to improve the quality of care that women with Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD) receive while using Assisted Reproductive Technology (ART). We’re inviting women with MS or NMOSD who have already used ART to take part in surveys and interviews to discuss if and where […]
Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial
To reduce the occurrence of autoimmune adverse events from the treatment of multiple sclerosis (MS) with alemtuzumab through the subsequent targeted use of rituximab. The hypothesis to be tested is that rituximab therapy following alemtuzumab treatment for MS will reduce the frequency of autoimmune adverse events. If this strategy proves to be safe and is […]